ARS Pharma climbs as EU regulator recommends approval for nasal spray

ARS Pharmaceuticals

28/06/2024 13:49

** Shares of drug developer ARS Pharmaceuticals  SPRY.O 
rise ~4.8% to $8.44 premarket
    ** Co says European Medicines Agency (EMA) has recommended
approval of its needle-free emergency treatment, EURneffy, for
allergic reactions
    ** ARS says European Commission, which usually follows EMA's
recommendation, is expected to decide on EURneffy in Q3 2024
    ** The nasal spray is also under review by U.S. Food and
Drug Administration; expected make its decision on Oct. 2
    ** Up to last close, stock up 46.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))